Karyopharm Therapeutics Inc. (KPTI) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jul 21, 2026
Karyopharm Therapeutics Inc. (KPTI)
A forensic read on Karyopharm Therapeutics Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Distress
Financial health
-58.6
Altman Z-score
Clean
Earnings quality
2
Forensic signals
0.6%
Revenue growth
Financial health / Altman Z-score above is based on book value, not market value — this free snapshot doesn't pull live market data. Treat it as a rough read, not the final word.
Karyopharm Therapeutics Inc. earns a F (Poor — capital at risk) forensic quality grade, and its Altman Z-score is -58.6, placing it in the Distress zone (based on book value, not market value, since this free snapshot doesn't pull live market data — treat this zone as a rough read, not the final word). 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-975.0%Return on invested capital.Return on invested capital is -975.0% in the latest fiscal year and slipping from -189% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
n/m (stock split)Share count (stock split).Diluted share count changed -87% over the last 3 years to FY2025, but that includes a large one-time change around FY2023 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw -48.9%/yr figure isn't a real buyback/dilution read here.
Key fundamentals
Latest Revenue$146.1M
Revenue Growth YoY+0.6%
Revenue CAGR (3yr)-2.4%
Net Margin-134.2%
Free Cash Flow$-59.1M
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Karyopharm Therapeutics Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about KPTI's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown